The AIDS Institute at the United States Conference on AIDS 2018

Join The AIDS Institute during the United States Conference on AIDS in Orlando, FL from September 6-9, 2018. 

Follow The AIDS Institute at USCA 2018 | | Twitter @AIDSadvocacy

Visit The AIDS Institute and AIDS Alliance for Women, Infants, Children, Youth & Families Booth #403


Thursday, September 6, 2018 | 8:00 am - 11:00 am | Orlando Ballroom N

Cultivating Advocates - Building Collaborations and Leveraging Resources Across Disease States

The Patient Advocacy Leaders Summit (PALS) initiative was developed in 2002 to bring together diverse patient advocacy leaders to improve advocacy capacity and identify ways to collaborate and unify the voices of many. 

The Institute will highlight PALS as a framework for how to effectively connect, educate and empower advocates to build collaborations and leverage resources to improve health and healthcare.  Attendees will have the opportunity to learn and/or refine advocacy skills from nationally recognized and highly acclaimed advocate Karen Moore, President and CEO of Moore Communications Group (MCG), who is the voice of advocacy in a number of industries. As a respected thought leader, she has shared her insights in advocacy, integrated communications and crisis communication through articles published in dozens of publications. She has also addressed more than 250 organizations on topics such as leadership, entrepreneurship, advocacy, crisis communications, marketing, and networking.

The mission of PALS is to improve the lives of those affected by disease and chronic health conditions, by educating and mobilizing health advocacy leaders to work collaboratively in developing impactful policy and advocacy solutions focused on the prevention and elimination of disease and chronic health conditions. 



Michael Ruppal, Executive Director, The AIDS Institute

Michelle Scavnicky, M.S., Associate Executive Director, The AIDS Institute 

Karen B. Moore, APR, CPRC, CEO, Author, Speaker, Moore Communications Group

Clint Crews, PALS Advisory Board Member

Mike Morris, PALS Ambassador


Thursday, September 6, 2018 | 1:45 pm - 3:45 pm | Orlando Ballroom N

Eliminating HCV Among People Living with HIV

In the United States, HIV and HCV co-infection continues to be a serious issue, with approximately 20% of people living with HIV (PLWHIV) co-infected with HCV. HCV infection increases the rate of liver disease progression, and liver disease has become the leading cause of non HIV-related death among people co-infected with HIV and HCV. With the advent of direct acting antivirals (DAAs) that can cure HCV, we have an important opportunity to eliminate HCV among people living with HIV and dramatically improve their health outcomes. This session will provide an overview of HIV and HCV co-infection, highlight key policy recommendations for eliminating HCV among PLWHIV, and explore state and local elimination efforts. 


Frank Hood, Senior Policy Associate, The AIDS Institute (moderator)

Corinna Dan, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services

Sonia CanzaterAssociate, Hepatitis Policy Project, O'Neill Institute for National & Global Health Law

Sainabou Katende, Hepatitis Prevention and Surveillance Team Lead, Texas Department of State Health Services

Alex Shirrefs, HIV/HCV Project Coordinator, Philadelphia Deprtment of Public Health

Nirah Johnson, Director of Capacity Building, Viral Hepatitis Program, NYC Department of Health Hygiene


Thursday, September 6, 2018 | 4:00 pm - 6:00 pm | Orlando Ballroom N

Meeting People Where They Are: Person-Centered Hepatitis Programming

People living with or most impacted by HCV need to be at the forefront of the work to address the epidemic. Stigma and discrimination continue to be a barrier to accessing prevention, testing, and cure so meeting people where they are and addressing their needs as a whole person in a non-judgmental way will be critical to overcoming existing barriers. This session will explore person-centered hepatitis programs including peer-based prevention and linkage in corrections and community settings, wound care as an entry point to HCV testing and linkage, and integrating hepatitis programming into substance use treatment.  


Alyssa Kitlas, Manager, Hepatitis, National Alliance of State & Territorial AIDS Directors (moderator)

Katie BurkViral Hepatitis Coordinator, San Francisco Department of Public Health

Mary SyllaDevelopment Director, Centerforce

Heather LuskExecutive Director, Hawaii Health and Harm Reduction Center

Jill WolfHepatitis C Program Director, Caring Ambassadors


Friday, September 7, 2018 | 9:00 am - 11:00 am | Orlando Ballroom N

Syndemics of HIV, Hepatitis, and Overdose

The opioid crisis in the United States is a public health emergency with drug overdose being the leading cause of death among people under 50. Increases in injection drug use are driving rates of HBV, HCV, and HIV to increase exponentially, with new HCV cases increasing 3.5-fold between 2010 and 2016. In order to address these intertwined epidemics, communities are working to expand access to syringe services programs (SSPs), substance use treatment including medication assisted treatment, hepatitis and HIV testing, as well as overdose prevention. This session will explore the syndemics of HIV, viral hepatitis, and the opioid crisis, and how health departments, community-based organizations, and communities are working to respond. Presenters:

Frank Hood, Senior Policy Associate, The AIDS Institute (moderator)

Sara ZeiglerAssociate Director for Policy, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention

Eleanor Cantrell, M.D., Health Director, LENOWISCO Health District

Wayne Smith, Director, Samaritan Ministry

Lee StorrowExecutive Director, North Caroline AIDS Action Network

Shana Geary, Hepatitis Surveillance Epidemiologist and Molecular HIV Surveillance Co-Coordinator, STD and Hepatitis Section and HIV/AIDS Section, Bureau of Communicable Diseases, Florida Department of Health


Friday, September 7, 2018 | 9:00 am - 11:00 am | Orlando Ballroom L

Ensuring Ryan White Funding Follows the Epidemic

In order to ensure people living with HIV have the care, treatment and support needed to be virally suppressed and begin to end HIV, it is imperative that the Ryan White HIV/AIDS Program be maintained and that its funding be distributed to those areas most affected and in need. The AIDS Institute examined how current funding is distributed by analyzing all 2017 Ryan White HIV/AIDS Program (RWHAP) formula and competitive grant awards based by each state and their current case counts. Using this analysis to provide context to the discussion, this session will engage experts on the provisions in the law that guide how Ryan White funding is distributed, and potential administrative options for making changes to funding distributions, including the award of supplemental funding. Additionally, proposed legislative formula changes contained in the Administration's FY19 budget will be discussed. Subject matter experts from the field will provide perspectives on how best Ryan White funding should be distributed to areas most in need to achieve the goal of ending the epidemic. 


Carl Schmid, Deputy Executibe Director, The AIDS Institute 

Stephanie Hengst, Senior Policy Associate, The AIDS Institute

Carolyn McAllaster, Clinical Professor of Law & Director, Southern HIV/AIDS Strategy Initiative (SASI), Duke University School of Law 

Ann Lefert, Senior Director, Policy & Legislative Affairs, National Alliance of State & Territorial AIDS Directors (NASTAD)

William McColl, Vice President of Policy and Advocacy, AIDS United

Graham Harriman, Director of Care and Treatment, HIV Prevention & Control, NYC Department of Health and Mental Hygiene

Kate McManus, MD, Assistant Professor, University of Virginia School of Medicine


Friday, September 7, 2018 | 2:00 pm - 4:00 pm | Orlando Ballroom N

Hepatitis Elimination as an Equity Issue

Hepatitis disproportionately impacts a number of communities in the United States. Incidence rates for American Indian/Alaskan Natives remain high relative to other groups. People of Asian and Pacific Islander descent make up less than 5% of the US, but account for over 50% of people living with HBV. Hispanics are 60% more likely to die from viral hepatitis than whites. And within five years, over 65% of people who inject drugs will become infected with HCV, but Medicaid and private insurance continue to impose restrictions that block the people most in need from getting access to a cure. Eliminating hepatitis will not be possible unless we explore it through the lens of equity. This session will discuss the importance of and provide examples of engaging communities most impacted by hepatitis and putting them at the forefront of our work. 


Alyssa Kitlas, Manager-Hepatitis, National Alliance of State & Territoritial AIDS Directors (moderator)

Corinna DanViral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, 'U.S. Department of Health and Human Services

Elton Naswood, Senior Program Analyst, Office of Minority Health Resource Center, U.S. Department of Health and Human Services 

Rhea Racho, Public Policy and Program Manager, Hepatitis B Foundation

Luis Mares, Director of Community Mobilization Programs, Latino Commission on AIDS

Robert Greenwald, Faculty Director, Center for Health Law and Policy Innovation, Harvard Law School


Saturday, September 8, 2018 | 9:00 am - 11:00 am | Celebration 12 & 13

Ensuring Federal Funding for Domestic HIV Programs

HIV is a public health issue whose response requires a combination of resources and programs for which the federal government has primary responsibility. In order to provide care, treatment and supportive services for PLWH, implement prevention programs, which now includes PrEP, and conduct research, numerous federal programs have been created and funded. The Trump Administration has proposed that some of them be scaled back, and altered others to address current challenges and priorities. Recently, funding levels have been stagnant, which questions how the U.S. will meet the goals of the National HIV/AIDS Strategy (NHAS). The workshop will examine these issues, discuss the current situation and explore opportunities for the future. 


Nick ArmstrongPolicy Associate, The AIDS Institute

Carl Schmid. Deputy Executive Director, The AIDS Institute

Kevin Fisher. Director, Policy, Data & Analytics, AVAC

Angela Johnson, Associate Director, Prevention, NASTAD

Dr. Kate McManus. Assistant Professor, University of Virginia School of Medicine

Matthew Rose. Policy and Advocacy Manager, NMAC

Lauren Killelea, Public Policy Manager, National AIDS Housing Coalition

Frank Hood, Senior Policy Associate, The AIDS Institute


Saturday, September 8, 2018 | 2:00 pm - 4:00 pm | Celebration 9

Addressing HIV Stigma in Older Women

People over the age of 50 account for 17% of all new HIV diagnoses in the US. Of that number, 1 in 4 are women. Research has demonstrated that stigma and discrimination are identified barriers to HIV prevention, treatment and care services. In addition, stigma and discrimination can undermine HIV prevention efforts by inducing fear and limiting individuals to seek HIV information. For women, particularly black and Hispanic women, there is a greater need to address stigma due to the cyclical relationship between stigma and HIV. The presenters will explore various common social barriers that affect older women. Topics to be covered include, ageism, stigma, discrimination, limited knowledge about HIV/AIDS, misconceptions, and underestimation of risk. Attendees will also receive access to resources designed to address HIV stigma in older women.


Michelle Scavnicky, M.S., Associate Executive Director, The AIDS Institute

Kimberly Molnar, M.Acc., Program Coordinator, The AIDS Institute 

Ivy Turnbull, PhD, Deputy Executive Director, AIDS Alliance for Women, Infants, Children, Youth & Families

Marilyn MeridaProgram Administrator, Florida Family AIDS Network